Recursion Pharmaceuticals, Inc. (RXRX) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Gil Blum
Needham & Company, LLC, Research Division

Good afternoon, everyone, and thank you for joining us on the first day of Needham & Company Healthcare Conference. My name is Gil Blum, and I’m a senior biotech analyst here at Needham & Company. It is my pleasure to have with me today Recursion’s Chief Financial Officer, Ben Taylor. As a reminder, any viewers who are watching through our conference portal are able to ask questions via the Ask a question box below the video feed window.

So Ben, maybe just starting with a bit of an introduction, setting the stage and just discussing some of the company’s priorities in 2026.

Ben Taylor
CFO & President of Recursion UK

Sure. Thanks, Gil, and really appreciate you having us at the conference. So ’26 has been — it’s really, if you think about it, a year that last year was transition because we had the merger that happened towards the end of ’24. And so we were doing a lot of reshaping the strategy, reshaping the financial structure, putting together the right pipeline. Now we’ve started to enter into that phase in ’26, where we’re looking at data readouts and partnership milestones on a more and more regular basis. So we already had our first proof-of-concept data readout with our FAP molecule and program moving forward, and now we’re in FDA discussions on that.

We’ve got 4 more clinical programs that are moving in besides that — behind that. But then also our partnership business, where we’ve already brought in over $500 million through our partnerships